

Supplementary Material: Cysteamine Eye Drops in Hyaluronic Acid Packaged in Innovative Single-Dose Systems: Stability and Ocular Biopermanence

Ana Castro-Balado ^{1,2,3†}, Enrique Bandín-Vilar ^{1,2,3†}, Andrea Cuartero-Martínez ^{2†}, Laura García-Quintanilla ^{1,2,3}; Gonzalo Hermelo-Vidal ², Xurxo García-Otero ^{3,4}, Lorena Rodríguez-Martínez ², Jesús Mateos ², Manuela Hernández-Blanco ⁵, Pablo Aguiar ⁴, Irene Zarra-Ferro ^{1,2}, Miguel González-Barcia ^{1,2}, Cristina Mondelo-García ^{1,2,*}, Francisco J. Otero-Espinar ^{3,*} and Anxo Fernández-Ferreiro ^{1,2,*}




Figure S1. COL Eye Drops System® used in the stability study, provided from Biomed Device.




Figure S2. Cystamine content with respect to the initial concentration throughout the study for each of the temperature settings (refrigeration/freezing) and presence/absence of nitrogen.




Figure S3. Speed-scan test at 25 °C of the cysteamine formulations with presence/absence of nitrogen at day 0, where the viscosity is measured at different revolutions per minute (rpm).




Figure S4. Speed-scan test at 25 °C of the cysteamine formulations stored at different temperature conditions and presence/absence of nitrogen at day 15, where the viscosity is measured at different rpm.




Figure S5. Speed-scan test at 25 °C of the cysteamine formulations stored at different temperature conditions and presence/absence of nitrogen at day 30, where the viscosity is measured at different rpm.